Cardiac Safety Services Market Report 2026

The cardiac safety services market size has grown rapidly in recent years. It will grow from $1.16 billion in 2025 to $1.29 billion in 2026 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to increasing complexity of clinical trial protocols, rising regulatory scrutiny on cardiac safety, growth in early-phase drug development activity, increased incidence of drug-induced cardiotoxicity concerns, expansion of outsourcing to specialized service providers.

The cardiac safety services market size is expected to see rapid growth in the next few years. It will grow to $1.94 billion in 2030 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to increasing demand for integrated cardiac safety platforms, rising adoption of remote monitoring technologies, expansion of decentralized clinical trials, growing focus on predictive cardiac safety analytics, increasing investment in advanced cardiac biomarkers. Major trends in the forecast period include increasing adoption of centralized ecg monitoring services, rising demand for real-time telemetry in clinical trials, growing use of advanced cardiac imaging in drug safety, expansion of thorough qt study requirements, enhanced focus on early-phase cardiac risk assessment.

The increasing aging population is anticipated to drive the growth of the cardiac safety services market in the coming years. An aging population refers to the rise in the median age within a population due to declining fertility rates and longer life expectancy. As the population grows older, the prevalence of cardiovascular diseases rises, creating a greater demand for cardiac safety services. Older adults require specialized care and management for geriatric syndromes in cardiac intensive care units, which can be supported by cardiac safety services. For example, in January 2024, the Population Reference Bureau, a US-based nonprofit organization, reported that the number of Americans aged 65 and older is expected to increase from 58 million in 2022 to 82 million by 2050, marking a 47% rise. The proportion of this age group within the total population is also projected to grow from 17% to 23% over the same period. Consequently, the expanding aging population is fueling the growth of the cardiac safety services market.

Major companies in the cardiac safety services market are focusing on launching next-generation solutions, such as AI and ML-powered cardiac safety tools, to strengthen their market position. These tools analyze ECG data to deliver detailed insights on the acquired continuous ECG signals, including assessments of data quality. The AI and ML algorithms are trained on extensive ECG datasets to ensure accurate and reliable outcomes. For example, in November 2023, Clario, a US-based healthcare company, introduced its new AI-powered ECG quality score tool to improve cardiac safety evaluations. The tool leverages a distinctive form of machine learning and artificial intelligence to enhance the quality of cardiac safety data. Sponsors can utilize this actionable intelligence to implement proactive corrections and gain confidence in data reliability. Clario’s AI tool complements its market-leading Early Precision QT (EPQT) early phase solution, potentially enabling the waiver of traditional Thorough QT (TQT) studies.

In October 2023, Motion Equity Partners, a private equity firm based in France, acquired Banook Group for an undisclosed sum. Through this acquisition, Motion Equity Partners intends to boost Banook Group's growth prospects and broaden its market presence, utilizing the firm's expertise and resources to foster innovation and improve operational efficiency within the company. Banook Group is a France-based technology company that specializes in digital solutions and services for the media and telecommunications industries.

Major companies operating in the cardiac safety services market are Laboratory Corporation of America Holdings, Banook Group Limited, Pharmaceutical Product Development LLC, Biotrial S.A., Certara Inc., Celerion Inc., Medpace Holdings Inc., Ncardia AG, Richmond Pharmacology Limited, SGS Société Générale de Surveillance SA, Clario, Eurofins Scientific SE, Spaulding Clinical Research LLC, ERT Inc., IQVIA Holdings Inc., Bioclinica Inc., ICON plc, BioTelemetry Inc., PPD Inc., Parexel International Corporation, Chiltern International Limited, Biomedical Systems, High Point Clinical Trials Center, Maastricht University Medical Centre+, CCBR-SYNARC, Medicalgorithmics S.A., Advarra Inc.

North America was the largest region in the cardiac safety services market in 2025. The regions covered in the cardiac safety services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cardiac safety services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the cardiac safety services market by increasing costs associated with imported diagnostic equipment, telemetry devices, ECG systems, and imaging technologies used across clinical trial services. Pharmaceutical and biotechnology companies in North America and Europe are most affected due to reliance on globally sourced cardiac monitoring hardware and software platforms, while Asia-Pacific faces higher costs for advanced imported devices. These tariffs are contributing to higher trial execution costs and extended study timelines. However, they are also encouraging service providers to invest in local equipment sourcing, regional service hubs, and in-house technology development to reduce long-term dependency on imports.

The cardiac safety services market research report is one of a series of new reports that provides cardiac safety services market statistics, including cardiac safety services industry global market size, regional shares, competitors with a cardiac safety services market share, detailed cardiac safety services market segments, market trends and opportunities, and any further data you may need to thrive in the cardiac safety services industry. This cardiac safety services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cardiac safety services involve providing support and assistance in monitoring heart health and in designing clinical trials and other research studies. These services generally assist with the planning of clinical trials and other investigations required to ensure cardiac safety.

The primary services of cardiac safety include ECG or Holter measurements, blood pressure monitoring, in vitro cardiac safety assessment, cardiovascular imaging, real-time telemetry monitoring, central over-read of ECGs, non-invasive cardiac imaging, physiologic stress testing, thorough QT studies, and other related services. Holter measurement is a type of portable electrocardiogram (ECG) that continuously records the heart's electrical activity over 24 hours or more while the patient is away from the clinic. The process involves Phase 1, Phase 2, and Phase 3, which are utilized by pharmaceutical and biopharmaceutical companies, contract research organizations, and academic and research institutions.

The cardiac safety services market includes revenues earned by companies by providing cardiac safety monitoring, ventricular arrhythmias, and cardiovascular performance services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.